OncoMatch

OncoMatch/Clinical Trials/NCT06921785

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Is NCT06921785 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tremelimumab and Rilvegostomig for hepatocellular carcinoma.

Phase 3RecruitingAstraZenecaNCT06921785Data as of May 2026

Treatment: Tremelimumab · Rilvegostomig · Bevacizumab · Atezolizumab — This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

WHO/ECOG 0–1

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systemic therapy

Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.

Cannot have received: anti-CTLA-4 therapy

Prior treatment with anti-CTLA-4

Cannot have received: anti-TIGIT therapy

Prior treatment with anti-TIGIT

Cannot have received: radiotherapy

Exception: palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment

Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment

Lab requirements

Blood counts

Adequate organ and bone marrow function measured during the screening period

Kidney function

Adequate organ and bone marrow function measured during the screening period

Liver function

Child-Pugh Score class A

Adequate organ and bone marrow function measured during the screening period

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Phoenix, Arizona
  • Research Site · Tucson, Arizona
  • Research Site · Palo Alto, California
  • Research Site · Santa Monica, California
  • Research Site · New Haven, Connecticut

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify